Treatment of advanced adrenocortical cancer (ACC): Data from 152 patients of the national and multicenter ICARO_GETHI/SEEN registry

#3573

Introduction: Adrenocortical carcinoma (ACC) is a rare tumor with a poor prognosis in stage IV with only one treatment regimen of chemotherapy (CT), etoposide, doxorubicin, and cisplatin (EDP) and mitotane with proven activity in a phase 3 trial.

Aim(s): To assess progression-free survival (PFS) and overall survival (OS) according to the treatment received in patients with advanced ACC.

Materials and methods: ICARO is a multicenter registry (29 hospitals) of patients with ACC. Survival was assessed using the Kaplan-Meier method. To adjust for confounding factors, multivariable Cox proportional hazards regression was performed.

Conference:

Presenting Author:

Authors: Álvarez-Escolá C, Ballester I, Garcia Donas J, Paja M, Iglesias C,

Keywords: Adrenocortical cancer, mitotane, chemotherapy, survival, registry,